{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:25:08Z","timestamp":1789831508600,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.det.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T01:16:58Z","timestamp":1563412618000},"page":"435-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Nonsurgical Treatments for Nonmelanoma Skin Cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"Alexandra","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Doerfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2019.05.003_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amepre.2014.08.036","article-title":"Prevalence and costs of skin cancer treatment in the US, 2002\u20132006 and 2007\u20132011","volume":"48","author":"Guy","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.det.2019.05.003_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jid.2013.304","article-title":"Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence","volume":"134","author":"Eisemann","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2133.2005.06799.x","article-title":"Skin cancer incidence and the ageing population","volume":"153","author":"Diffey","year":"2005","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.003_bib4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.jid.5700740","article-title":"Quality of life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"127","author":"Chren","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.003_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clindermatol.2017.10.009","article-title":"Nonsurgical treatment of nonmelanoma skin cancer in the mature patient","volume":"36","author":"\u010ceovi\u0107","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib6","first-page":"26","article-title":"Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies","volume":"9","author":"Lanoue","year":"2016","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.clindermatol.2013.08.020","article-title":"Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies","volume":"31","author":"Bahner","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.12703\/P7-53","article-title":"Advances in the management of basal cell carcinoma","volume":"7","author":"Lewin","year":"2015","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.det.2019.05.003_bib9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/DSS.0000000000000478","article-title":"Consensus for nonmelanoma skin cancer treatment. Part II: squamous cell carcinoma, including a cost analysis of treatment methods","volume":"41","author":"Kauvar","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2019.05.003_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/DSS.0000000000000296","article-title":"Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods","volume":"41","author":"Kauvar","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2019.05.003_bib11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1524-4725.1997.tb00453.x","article-title":"Cryosurgery for cutaneous malignancy: an update","volume":"23","author":"Kuflik","year":"1997","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2019.05.003_bib12","first-page":"297","article-title":"Cryosurgery for skin cancer: 30-year experience and cure rates","volume":"30","author":"Kuflik","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2019.05.003_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1524-4725.1996.tb00588.x","article-title":"Cryosurgery in the treatment of basal cell carcinoma","volume":"22","author":"Mallon","year":"1996","journal-title":"Dermatol Surg"},{"issue":"12","key":"10.1016\/j.det.2019.05.003_bib14","first-page":"1118","article-title":"Cutaneous cryosurgery","volume":"86","author":"Zimmerman","year":"2012","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.det.2019.05.003_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2133.1988.tb03205.x","article-title":"Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery","volume":"119","author":"Holt","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/0190-9622(91)70160-4","article-title":"The five-year cure rate achieved by cryosurgery for skin cancer","volume":"24","author":"Kufik","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.003_bib17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.006","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Bichakjian","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.003_bib18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0190-9622(92)70144-5","article-title":"Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection","volume":"26","author":"Rowe","year":"1992","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib19","first-page":"433","article-title":"5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction","volume":"33","author":"Gross","year":"2007","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2019.05.003_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/120347540300700201","article-title":"Topical treatment of Bowen\u2019s disease with 5-fluorouracil","volume":"7","author":"Bargman","year":"2003","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.det.2019.05.003_bib21","first-page":"1431","article-title":"Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review","volume":"15","author":"Love","year":"2009","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.003_bib22","first-page":"447","article-title":"Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy","volume":"7","author":"Warshauer","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.003_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaad.2006.04.004","article-title":"Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma","volume":"55","author":"Peris","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe","volume":"152","author":"Schulze","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1440-0960.2006.00265.x","article-title":"Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study","volume":"47","author":"Vun","year":"2006","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib26","first-page":"507","article-title":"Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up","volume":"6","author":"Schiessl","year":"2007","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib27","first-page":"677","article-title":"Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe","volume":"18","author":"Gollnick","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09546630701557965","article-title":"A\u00a0randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal\u00a0cell carcinoma","volume":"19","author":"Ezughah","year":"2008","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2019.05.003_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1067\/mjd.2001.113689","article-title":"Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6- week dose\u2013response trial","volume":"44","author":"Marks","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1590\/S1807-59322009001000005","article-title":"Treatment of cutaneous tumors with topical 5% imiquimod cream","volume":"64","author":"Alessi","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.det.2019.05.003_bib31","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1468-3083.2008.03019.x","article-title":"Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series","volume":"23","author":"Ruiz-Villaverde","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2019.05.003_bib32","first-page":"318","article-title":"Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study","volume":"85","author":"Quirk","year":"2010","journal-title":"Cutis"},{"key":"10.1016\/j.det.2019.05.003_bib33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1365-2133.2002.05069.x","article-title":"Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion","volume":"147","author":"Sterry","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib35","doi-asserted-by":"crossref","first-page":"25912","DOI":"10.3390\/ijms161025912","article-title":"Combined treatments with photodynamic for non-melanoma skin cancer","volume":"16","author":"Lucena","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.det.2019.05.003_bib36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/dth.12148","article-title":"Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%","volume":"27","author":"Cantisani","year":"2014","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2019.05.003_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/CCID.S109531","article-title":"Treatment of superficial basal cell carcinoma with ingenol mebutate gel 0.05%","volume":"9","author":"Bettencourt","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1440-0960.2010.00626.x","article-title":"PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized control phase IIa trial","volume":"51","author":"Siller","year":"2010","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.003_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaad.2016.01.050","article-title":"The effect of topical diclofenac 3% and calcitriol 3 \u03bcg\/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial","volume":"75","author":"Brinkhuizen","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib40","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2230.2005.01867.x","article-title":"Two cases of Bowen\u2019s disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel","volume":"30","author":"Dawe","year":"2005","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.det.2019.05.003_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2133.2007.07859.x","article-title":"Does progression from actinic keratosis and Bowen\u2019s disease end with treatment: diclofenac 3% gel, an old drug in a new environment?","volume":"156","author":"Patel","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaad.2006.06.006","article-title":"Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus","volume":"56","author":"Braathen","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib43","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/archderm.134.7.821","article-title":"Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy","volume":"134","author":"Fink-Puches","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cancers8100090","article-title":"Photodynamic therapy for non-melanoma skin cancer","volume":"8","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.det.2019.05.003_bib45","doi-asserted-by":"crossref","first-page":"23300","DOI":"10.3390\/ijms161023300","article-title":"Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma","volume":"16","author":"Savoia","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.det.2019.05.003_bib46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archderm.143.9.1131","article-title":"Five-year follow-up of a randomized, prospective trial of topical methyl amino levulinate photodynamic therapy vs. surgery for nodular basal cell carcinoma","volume":"143","author":"Rhodes","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.003_bib47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2133.2003.05033.x","article-title":"Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease","volume":"148","author":"Salim","year":"2003","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.003_bib48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.1994.112","article-title":"Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer","volume":"69","author":"Cairnduff","year":"1994","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.det.2019.05.003_bib49","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/jdv.14164","article-title":"Effectiveness of photodynamic therapy in Bowen's disease: a retrospective observational study in 423 lesions","volume":"31","author":"Zaar","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2019.05.003_bib50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0360-3016(01)01656-X","article-title":"Radiotherapy for epithelial skin cancer","volume":"51","author":"Locke","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.det.2019.05.003_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/bjc.1997.343","article-title":"Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study","volume":"76","author":"Avril","year":"1997","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.det.2019.05.003_bib52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2010.03.027","article-title":"The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review","volume":"65","author":"Alam","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jdermsci.2015.02.007","article-title":"Hedgehog signaling in basal cell carcinoma","volume":"78","author":"Otsuka","year":"2015","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.det.2019.05.003_bib54","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/OTT.S130910","article-title":"Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas","volume":"10","author":"Jain","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10.1016\/j.det.2019.05.003_bib55","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.det.2019.05.003_bib56","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/jco.2014.32.15_suppl.9013","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC study","volume":"32","author":"Sekulic","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2019.05.003_bib57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jamadermatol.2016.5058","article-title":"A\u00a0novel alternate dosing of vismodegib for treatment of patients with advanced basal cell carcinomas","volume":"153","author":"Becker","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2019.05.003_bib58","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.14694\/EdBook_AM.2014.34.e397","article-title":"Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need","author":"Palyca","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.det.2019.05.003_bib59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fonc.2016.00199","article-title":"Treatment of elderly patients with squamous cell carcinoma of the head and neck","volume":"6","author":"Szturz","year":"2016","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.det.2019.05.003_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/COC.0000000000000228","article-title":"Concurrent Radiotherapy with cetuximab or platinum-based chemotherapy for locally advanced cutaneous squamous cell carcinoma of the head and neck","volume":"41","author":"Lu","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.det.2019.05.003_bib61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic therapy in advanced cutaneous squamous cell Carcinoma (CSCC): the roswell park experience and a review of the literature","volume":"39","author":"Jarkowski","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2019.05.003_bib62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.det.2019.05.003_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","article-title":"Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma","volume":"51","author":"Ritprajak","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.det.2019.05.003_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:45:42Z","timestamp":1760006742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863519300452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0733863519300452"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2019.05.003","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonsurgical Treatments for Nonmelanoma Skin Cancer","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}